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distal to the aortic crossclamp, that is, after ischemia. The dif-
ferent results are probably related to how fast the memantine
can cross the blood-brain barrier. Had the intra-arterial infu-
sion been performed over a 30-minute period before aortic
crossclamping, which of course is impractical, the results
might have been different. We have found that a 20- to 30-
minute period is usually necessary for effects of pharmaco-
logic agents (including those of adenosine and adenosine
triphosphate) to significantly appear in the brain interstitial
fluid after intravenous administration (bolus or infusion).
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Reply to the Editor:
My colleagues and I thank Miyamoto and Miyamoto for
their interest and comments on our recent article regarding
the N-methyl-D-aspartate (NMDA) blocker memantine.1
As we are aware of the protective effect of hypothermia on
the release of excitatory amino acids, we have tried to keep the
rectal temperature in a normothermic range assuming that the
rectal temperature will reflect more accurate spinal cord tem-
perature than esophageal temperature. However, we will addi-
tionally monitor esophageal temperature in future experiments.
With respect to our anesthesia protocol, a comparable
experiment investigating the influence of anesthetics on neu-
rologic recovery showed that ketamine treatment reduced
acute paraplegia but increased delayed paraplegia.2 In our
study, the control group did not show a protective effect of
ketamine compared with the groups treated with memantine.
Volatile anesthetics and nitrous oxide are suppressive to myo-
genic motor-evoked responses,3 but ketamine is recommend-
ed as a suitable supplement to opioid/nitrous oxide anesthe-
sia in men.4 In our experiments we used ketamine to keep the
experimental conditions constant and to avoid false positive
depression of motor-evoked potentials due to the influence of
an anesthetic.
In regard to the different applications of memantine, we
assumed that intra-arterial infusion of memantine into the
clamped aortic segment would result in better protection than
administering the drug systematically. We were surprised by
the fact that the systemic group did better than the intra-aor-
tic group. We concur that this phenomenon was due to the
slow crossing of memantine through the blood-brain barrier.
Marek Ehrlich, MD
Department of Cardiothoracic Surgery
Mount Sinai Medical Center
One Gustave Levy Place
Box 1028
New York City, NY 10029
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Possible mechanism of calcification of the BioCor
stentless mitral valve treated with the No-React
formula
To the Editor:
I read with great interest the brief communication by Milo
and associates regarding the possible mechanism of calcifica-
tion of the BioCor stentless mitral valve (BioCor,
Belohorizonte, Brazil) treated with the No-React anticalcifi-
cation formula (Shelhigh Inc, Millburn, NJ) in 2 adolescents. 
These 2 children were 13 years old at time of implantation.
Both had mitral and aortic endocarditis. Both needed double
valve replacement. I assume anticoagulation was not an
option. Milo and associates elected to implant the BioCor
stentless aortic and mitral valves treated with No-React anti-
calcification formula in both children. The BioCor mitral
valve was a newly designed porcine mitral valve specially fit-
ted to be implanted in the mitral position. Milo and col-
leagues can be congratulated for the proficient implantations
of the double valves in both children. 
Mechanism of calcification. Once a valve is inflamed or
infected, calcification will occur in a few months or a few
years. Furthermore, nonmoving cusps tend to calcify early.
The BioCor stentless mitral valve is still an experimental
valve design (Fig 1). The major drawback is the length limi-
tations of the chordae. If the patient has a large heart, the
chordae will be too short. This mismatch of chordal length
can cause extra tension and rupture of the chordae. Further-
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 4
Letters to the Editor   771
more, if this mitral stentless valve is implanted in a child and
the heart grows, the chordae are pulled down toward the ven-
tricle, preventing the normal movement of the cusps. In both
cases, the mitral chordae ruptured because of undue tension.
Nonmoving cusps will eventually calcify as well.
Interestingly, in 1 child the aortic valve had a minimal amount
of calcification, and the second child had a normal valve 3
years after the operation. The valve was not explanted and is
still functioning well years after the operation.
I differ with Milo and associates about the causes of calcifi-
cation of the BioCor mitral valve treated with the No-React for-
mula. The BioCor stentless mitral valve is an unproved design.
Its implantation and proper function depend on many factors,
which can cause the valve to stop moving or even tear without
any degeneration. The fact that these patients had severe endo-
carditis could also be a factor that caused inflammation or sub-
clinical endocarditis followed obviously by calcification.
Clinical experience with BioCor stentless valves treated with
the No-React formula so far shows that these valves resist cal-
cification. Von Oppell and coworkers1 recently presented an
experience with the BioCor No-React stentless aortic valve in
52 consecutive patients. The mean age was 44 ± 17 years, and
the youngest patient was 16 years at the time of implantation.
The follow-up period is already 5 years (first implant in 1994).
Although this population is considered to be very young for a
bioprosthesis, no calcification has been seen yet. 
Clinical experience with the pulmonic porcine valve con-
duit treated with the No-React formula has been reported in
infants younger than 1 year, with a follow-up period of 18
months. No calcification has been seen so far.2 In these young
children calcification of homografts can be seen as early as 4
months after implantation.3 The fact that the aortic stentless
valve treated with the No-React formula resisted calcification
whereas the BioCor mitral stentless valve did not, in the same
patients, gives further credence to the claim that anticalcifica-
tion treatment cannot compensate for nonfunctioning or
infected valves. I believe that when there is a need to implant
a bioprosthesis in the mitral position in young patients, it
should be a proven design. 
The stentless mitral xenograft is a complex valve that needs
more evaluation. It should not be recommended for use in
children. The conclusions of Milo and associates I believe
should concentrate on the difference between the aortic and
mitral stentless valves in the presence of endocarditis. After
all, if the native valve calcifies after an infection, it will be
presumptuous to expect any anticalcification treatment to be
superior to the patient’s own native tissue.
Shlomo Gabbay, MD
Department of Cardiothoracic Surgery
University of Medicine and Dentistry of New Jersey
New Jersey Medical School
185 South Orange Ave
Newark, NJ 07103-2757
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Reply to the Editor:
Dr Gabbay was deeply involved in choosing the type of
stentless valves used in these 2 children and in observing
them after the operation. We informed him of the results of all
echocardiographic studies done on the children. Early post-
operative studies in the 2 children showed that both leaflets of
the stentless mitral valves had a full spectrum of movement
and that both coaptation and closure were good. In fact, an
inexperienced observer could barely recognize an implanted
prosthesis in the mitral position. Furthermore, one of the
authors (Dr Bar-El) was invited to present these promising
early results at the 1996 meeting of The Society of Thoracic
Surgeons at Gabbay’s presentation on the No-React detoxifi-
cation process (Shelhigh Inc, Millburn, NJ).1 One month
later, as the children’s hearts began to recover and return to
near normal size, we noted a progressive prolapse of both
leaflets. As the prolapse steadily increased, we began to con-
sider replacing the valves, not because of the length of the
chordae tendineae, but because of the prolapse itself.
However, calcification, not the prolapse, determined the time
of surgical intervention. Our follow-up echocardiographic
data do not support Gabbay’s contention that torn chordae
resulted from undue tension. We believe that the early
biodegradation of the valve resulted in calcification, which
led to rupture of the chordae.
We do believe that a stentless mitral prosthesis that incor-
porates the entire subvalvular apparatus may cause problems
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Fig 1. The BioCor stentless mitral valve. It is apparent how
short the chordae are. Since the length of these chordae is
fixed and limited, mismatch can occur leading to chordal rup-
ture or stiffening. The relatively large amount of pericardial
tissue used to strengthen the chordae causes further limitation
in the movement of the cusps.
